Harmonic Pharma, the boosting research start-up
Harmonic Pharma makes the front page of “L’Est Républicain” journal today!
Harmonic Pharma will be present on the LORIA laboratory stand in “Cité Santé”: the first E-health exhibition in Nancy which aims to create new synergies. Healthcare professionals, ICT companies, start-ups, pharmaceutical laboratories, institutions and general public are invited in Nancy on Friday, 1st and Saturday, April 2nd to meet and test innovations in health. The objective : ”breaking barriers between actors of the E-health“, explained Isabelle Margo, founder of the event.
GES Polypharmacology Fingerprints: A Novel Approach for Polypharmacology
This article has been selected for making the front cover illustration of the March 2014 issue of Journal of Chemical Information and Modeling.
LBS – Le Bois Santé
Harmonic Pharma has been working on an innovative approach focused on therapeutic valorisation of natural compounds deriving from wood, in a circular economy context. The project named Le Bois Santé (LBS) deals with a natural source of molecules which is part of a starting raw material (parts of wood) used in an industrial process and considered as waste until the beginning of the project.
Harmonic Pharma, Institut Curie deal
Harmonic Pharma, Villers les Nancy, France Institut Curie, Paris, France Business: Cancer Harmonic partnered with Curie-Cancer, part of Institut Curie, to develop molecules in the biotech’s pipeline to treat breast, lung and eye cancers. Harmonic will receive access to mouse cancer models from the institute for screening its compouds against an undisclosed cellular membrane receptor target.
Curie-Cancer and Harmonic Pharma sign partnership agreement
Curie-Cancer, the body responsible for developing Institut Curie’s industry partnership activities and Harmonic Pharma, which is developing solutions for extending the therapeutic application of compounds already on the market, announce today that they have entered into a research collaboration aimed at exploring the anti-cancer activity of several molecules in Harmonic Pharma’s portfolio.